Intragastric Balloon: The Orbera365™ IGB System is to be used in conjunction with a long-term supervised diet and behavior modification program designed to increase the possibility of long-term weight loss maintenance. The IGB is placed in the stomach and filled with sterile saline, causing it to expand into a spherical shape. The filled IGB is designed to occupy space and move freely within the stomach, potentially altering appetite and satiety to achieve weight loss.
Study summary
This is a prospective, multi-center, standard of care registry offered to subjects in the EU only that have already agreed to receive the Orbera365™ Intragastric Balloon (IGB) System for weight loss. Subjects that agree to participate in the registry will have data reported associated with standard of care weight management visits during the time the device is implanted (in-dwell period), with an additional visit 30 days after the removal procedure.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Subject is ≥ 18 years of age
2. Subject meets the indicated population for the device according to the Instructions for Use (IFU) including obese patients with the BMI of 30-50 kg/m2 for weight loss and patients with BMI 40 kg/m2 and above or a BMI of 35 kg/m2 with comorbidities before obesity or another surgery, unless contraindicated.
3. Subject is able to read, understand, and sign a written Informed Consent Form to participate in the registry
Exclusion Criteria:
1. Subject is planning on becoming pregnant during the one year following study device placement
2. Subject will complete follow-up visits at a location that the treating physician does not practice
3. Subjects who are unable or unwilling to take prescribed proton pump inhibitor medication for the duration of the device implant.
4. Current use or use within the three months before the baseline visit of over-the-counter or prescribed weight loss supplements/medications.
5. Subjects who have conditions that are contraindicated for Orbera365™ IGB System as per the IFU, including, but not limited to:
* The presence of more than one IGB at the same time.
* Any inflammatory disease of the gastrointestinal tract including esophagitis, gastric ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn's disease
* Potential upper gastrointestinal bleeding conditions
* A large hiatal hernia of \> 5cm or a hernia ≤ 5 cm associated with severe or intractable gastro- esophageal reflux symptoms
* A structural abnormality in the esophagus or pharynx such as a stricture or diverticulum that could impede passage of the delivery catheter and/or an endoscope
* Achalasia, symptoms suggestive of delayed gastric emptying, or presence of any other severe motility disorder that that may pose a safety risk during placement or removal of the device.
* Gastric Mass.
* Severe coagulopathy.
* Taking aspirin, anti-inflammatory agents, anticoagulants or other gastric irritants and not under medical supervision.
* Prior surgery involving the esophagus, stomach, and duodenum or bariatric surgery
Primary outcome measure(s)
Rate of Subjects with Serious Adverse Events — Up to 12 months The rate of subjects with serious adverse events of interest associated with the extended length of the study device in-dwell time (between 6 and 12 months) and requiringe hospitalization, endoscopic or surgical intervention, or are life-threatening. Adverse events of interest include gastric outlet obstruction, spontaneous deflation that leads to obstruction, hyperinflation, and removal complications related to airway obstruction or esophageal laceration / perforation associated with compromised balloon integrity.
Rate of Treatment Completers — Up to 12 months The rate of Treatment Completers that achieve ≥10% percent Total Body Weight Loss (%TBWL) at time of study removal procedure. Treatment Completer is defined as maintaining device therapy for the prescribed maximum allowed in-dwell period (up to12 months) or successfully achieving weight loss goal (e.g., at least 5% TBWL) and an early device removal for a reason other than an adverse event.
Trial sites (4)
Facility
City
Region
Status
OB Klinika
Prague
Czechia
Recruiting
EndoBes - Centre Medico Teknon
Barcelona
Spain
Recruiting
Dorsia Clinic, Madrid Spain
Madrid
Spain
Recruiting
UHCW NHS Trust
Coventry
West Midlands
Not Yet Recruiting
More Boston Scientific Corporation trials in the UK
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.